This little-known biotech stock is a buy that’s primed to double in price, Goldman says
- Posted on January 17, 2025
- By CNBC
- 3 Views
This little-known biotech stock is a buy that’s primed to double in price, Goldman says
Shares of MoonLake Immunotherapeutics could surge nearly 98% from here, according to Goldman Sachs.
